Coronary Artery Disease, Overweight
Conditions
Keywords
Coronary Artery Disease, Inflammation, Overweight, Metabolic Syndrome, Salsalate
Brief summary
The hypothesis is that western lifestyle, with sedentary behaviors and caloric excess promote a chronic, subacute inflammatory state that participates in the development and progression of atherosclerosis. We will evaluate the effects of targeting inflammation using the anti-inflammatory drug salsalate, compared to placebo, on coronary artery plaque volume assessed by multi-detector computed tomographic angiography (MDCTA). The TINSAL-CVD study is a randomized, double-masked, placebo-controlled, 2 arm, clinical trial. The purpose of the study is to compare the effect of salsalate or placebo on sub-acute inflammation and coronary plaque, in people with cardiovascular disease. Participants are randomized to active intervention (salsalate) or placebo interventions for a period of 30 months. The primary endpoint is change in plaque volume in the coronary arteries assessed by MDCTA from baseline to 30 months.
Detailed description
OBJECTIVE: To determine whether targeting inflammation using salsalate compared with placebo reduces progression of noncalcified coronary artery plaque. DESIGN, SETTING, AND PARTICIPANTS: In the Targeting Inflammation Using Salsalate in Cardiovascular Disease (TINSAL-CVD) trial participants were randomly assigned to 30 months of salsalate or placebo in addition to standard, guideline-based therapies. Randomization was computerized and centrally allocated, with patients, health care professionals, and researchers masked to treatment assignment. Participants were overweight and obese statin-using patients with established, stable coronary heart disease. INTERVENTIONS: Salsalate (3.5 g/d) or placebo orally over 30 months. MAIN OUTCOMES AND MEASURES: The primary outcome was progression of noncalcified coronary artery plaque assessed by multidetector computed tomographic angiography. Secondary outcomes were other measures of safety and efficacy.
Interventions
DRUGSalsalate
Salsalate, 500 mg, seven tablets daily by mouth, divided into two doses, for 30 months
DRUGPlacebo
Placebo matched to Salsalate, seven tablets daily by mouth, divided into two doses, for 30 months
Sponsors
Beth Israel Deaconess Medical Center
Tufts Medical Center
National Heart, Lung, and Blood Institute (NHLBI)
Joslin Diabetes Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
21 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Eligibility will be based upon the presence of established coronary artery disease including * previous myocardial infarction (≥6 months ago), or * previous coronary bypass surgery (\> 12 months ago), or * stable angina, or * significant non-calcified plaque in at least one coronary artery, or * abnormal exercise tolerance test or * an area of reversible ischemia on nuclear imaging study or pharmacologic stress, with subsequent revascularization, or angioplasty, or * abnormal exercise treadmill stress test with or without nuclear imaging or echocardiography with the following exclusions: Exclusions based on nuclear imaging: 1. Transient cavity dilation 2. More than one vascular territory involved with reversible defect (multiple defects) 3. Reversible defects involving the anterior wall, septum or apex (LAD territory) Exclusions based on echocardiography imaging: 1. More than one vascular territory involved with inducible wall motion abnormalities (multiple defects) 2. Inducible wall motion abnormalities involving the anterior wall, septum or apex (LAD territory) Subjects should be at list 6 months after a myocardial infarction and/or revascularization procedure to be eligible. In addition, subjects must be: 1. aged 21- 75 years inclusive, 2. BMI ≥ 27 kg/m2 and ≤ 35 kg/m2 if female and ≤ 40 kg/m2 if male (a BMI ≥24.5 for subjects from Asian origin) 3. on a stable dose of an HMG CoA reductase inhibitor (statin) for 1 month at screening or unable to tolerate a statin, 4. have normal renal function, (note estimated creatinine clearance calculated using Cockcroft-Gault (CG) equation ≥60 at screening \[eCrCLCG (ml/min) = \[(140 - age) x weight (kg)\]/\[SCr(mg/dl) x 72\] x \[0.85 if female\], 5. have liver function (ALT, AST) \< 3 times upper limits of normal), 6. normal thyroid function (on stable dose replacement therapy is acceptable), 7. if women are of child bearing potential they must have a pregnancy test prior to the CT angio and use contraception for the remainder of the study 8. patients with T2D must have a fasting glucose of ≤ 200 mg/dl at screening and cannot be treated with thiazolidinedione class agents or insulin or Extendin-4 (Byetta) therapy. Subjects must be willing to have at least three visits at the Beth Israel-Deaconess Medical Center/Joslin Diabetes Center with a baseline and a 30-month follow-up series of imaging studies including CT angiography of the coronary arteries and imaging of the aorta, abdominal adiposity and liver, and interim visit at 1 year.
Exclusion criteria
1. Unstable angina (increase in frequency or severity of anginal episodes or development of chest pain at rest) 2. significant obstructive disease (≥ 70%) in left main coronary artery, ostial LAD or three-vessel disease by MDCTA 3. Significant heart failure (NYHA class III and IV) 4. Current atrial fibrillation or Wolf-Parkinson-White (WPW) syndrome 5. Allergy to beta-blocker in subjects with resting heart rate \> 65 bpm 6. Systolic blood pressure \> 160 mm Hg 7. Diastolic BP \> 100 mm Hg 8. Persons with allergies to contrast material 9. History of asthma if unable to tolerate beta blocker 10. Allergy to iodinated contrast material or shellfish 11. Allergy to nitroglycerin 12. BMI \> 35 kg/m2 if female and \> 40 kg/m2 if male 13. Body weight \> 350 lbs 14. Use of drugs for weight loss \[e.g. Xenical (orlistat), Meridia (sibutramine), Acutrim (phenylpropanolamine) or similar over-the counter medications\] within three months of screening 15. Surgery within 30 days of screening 16. History of acquired immune deficiency syndrome or human immunodeficiency virus (HIV) 17. Poor mental function or history of dementia/ Alzheimer's Disease or on medications used for treatment of dementia \[e.g. Tacrine (Cognex), Rivastigmine (Exelon), Galantamine (Razadyne, Reminyl), Donepezil (Aricept), Memantine (Namenda)\] or any other reason to expect patient difficulty in complying with the requirements of the study 18. Medicine for erectile dysfunction within 72 hours prior to MDCTA 19. History of significant chronic rheumatologic or other chronic inflammatory disease (including foot ulcers) 20. Prior hemorrhagic stroke 21. persons with known aspirin allergy 22. Use of continuous oral corticosteroid treatment (more than 2 weeks), or patients requiring corticosteroids within 3 months 23. Anti-diabetic medication including thiazolidinedione (pioglitazone or rosiglitazone), or insulin or Extendin-4 (Byetta) 24. History of peptic ulcer or gastritis within 5 years 25. Positive stool guaiac 26. Hemoglobin 2 standard deviations below normal 27. Low platelet count (2 standard deviations below normal) 28. Known bleeding disorder 29. Coumadin (warfarin compounds) 30. History of type 1 diabetes and/or history of ketoacidosis 31. Daily use of NSAIDS (including salsalate) for arthritis 32. History of malignancy, except subjects who have been disease-free for greater than 5 years, or whose only malignancy has been basal or squamous cell skin carcinoma 33. History of drug or alcohol abuse, or current weekly alcohol consumption \>14 units/week (1 unit = 1 beer, 1 glass of wine, 1 mixed cocktail containing 1 ounce of alcohol) 34. Use of probenecid (Benemid, Probalan), sulfinpyrazone (Anturane) or other uricosuric agents 35. Chronic tinnitus.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Non-calcified Plaque Volume in the Coronary Arteries Assessed by MDCTA From Baseline to 30 Months | Baseline to 30 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Cholesterol | Baseline to 30 mo | secondary |
| Change in Inflammation Marker: CRP | baseline to 30 mo | Secondary outcome of change in inflammation marker CRP |
| Change in Inflammation in the Liver Associated With Nonalcoholic Steatohepatitis (NASH), ALT | baseline to 30 mo | Secondary outcome, change in liver inflammation associated with NASH: ALT |
Countries
United States
Participant flow
Pre-assignment details
340 subjects signed consent and were screened for eligibility.
Participants by arm
| Arm | Count |
|---|---|
| 1- Active Pharmacologic Salsalate
Salsalate: Salsalate, 500 mg, seven tablets daily by mouth, divided into two doses, for 30 months | 127 |
| 2- Placebo Placebo
Placebo: Salsalate Placebo, seven tablets daily by mouth, divided into two doses, for 30 months | 124 |
| Total | 251 |
Baseline characteristics
| Characteristic | Total | 1- Active Pharmacologic | 2- Placebo |
|---|---|---|---|
| Age, Continuous | 60.8 years STANDARD_DEVIATION 7 | 61.5 years STANDARD_DEVIATION 6.8 | 60.1 years STANDARD_DEVIATION 7.2 |
| Region of Enrollment United States | 251 participants | 127 participants | 124 participants |
| Sex: Female, Male Female | 15 Participants | 9 Participants | 6 Participants |
| Sex: Female, Male Male | 236 Participants | 118 Participants | 118 Participants |
| Statin use | 248 participants | 126 participants | 122 participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 127 / 127 | 112 / 124 |
| serious Total, serious adverse events | 33 / 127 | 32 / 124 |
Outcome results
Primary
Change in Non-calcified Plaque Volume in the Coronary Arteries Assessed by MDCTA From Baseline to 30 Months
Time frame: Baseline to 30 months
Population: Intention to Treat
| Arm | Measure | Value (MEAN) |
|---|---|---|
| 1- Active Pharmacologic | Change in Non-calcified Plaque Volume in the Coronary Arteries Assessed by MDCTA From Baseline to 30 Months | 0 mm^3 |
| 2-Placebo | Change in Non-calcified Plaque Volume in the Coronary Arteries Assessed by MDCTA From Baseline to 30 Months | 0 mm^3 |
Secondary
Change in Cholesterol
secondary
Time frame: Baseline to 30 mo
| Arm | Measure | Value (MEAN) |
|---|---|---|
| 1- Active Pharmacologic | Change in Cholesterol | 5.1 mg/dL |
| 2-Placebo | Change in Cholesterol | 2.0 mg/dL |
Secondary
Change in Inflammation in the Liver Associated With Nonalcoholic Steatohepatitis (NASH), ALT
Secondary outcome, change in liver inflammation associated with NASH: ALT
Time frame: baseline to 30 mo
| Arm | Measure | Value (MEAN) |
|---|---|---|
| 1- Active Pharmacologic | Change in Inflammation in the Liver Associated With Nonalcoholic Steatohepatitis (NASH), ALT | -1.1 U/L |
| 2-Placebo | Change in Inflammation in the Liver Associated With Nonalcoholic Steatohepatitis (NASH), ALT | -0.6 U/L |
Secondary
Change in Inflammation Marker: CRP
Secondary outcome of change in inflammation marker CRP
Time frame: baseline to 30 mo
| Arm | Measure | Value (MEAN) |
|---|---|---|
| 1- Active Pharmacologic | Change in Inflammation Marker: CRP | -0.1 mg/L |
| 2-Placebo | Change in Inflammation Marker: CRP | -0.1 mg/L |